NCT02783820View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Malaria
Interventions
DRUG

MMV390048 40 mg

DRUG

Placebo to match MMV390048 40 mg

DRUG

MMV390048 80 mg

DRUG

Placebo to match MMV390048 80 mg

DRUG

MMV390048 120 mg

DRUG

Placebo to match MMV390048 120 mg

Trial Locations (1)

QLD 4006

Q Pharm Clinics, Herston

Sponsors
All Listed Sponsors
collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

collaborator

Q-Pharm Pty Limited

INDUSTRY

collaborator

QIMR Berghofer Medical Research Institute

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT02783820 - Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A | Biotech Hunter | Biotech Hunter